- $1.37bn
- $1.35bn
- $541.32m
Annual income statement for CTS, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 513 | 587 | 550 | 515 | 541 |
| Cost of Revenue | |||||
| Gross Profit | 185 | 211 | 191 | 188 | 208 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 436 | 494 | 475 | 444 | 459 |
| Operating Profit | 76.5 | 93 | 75.1 | 71.2 | 82.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -60.9 | 80.7 | 75.2 | 68.6 | 83.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -41.9 | 59.6 | 60.5 | 55.5 | 65.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.9 | 59.6 | 60.5 | 55.5 | 65.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -41.9 | 59.6 | 60.5 | 55.5 | 65.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.26 | 1.89 | 2.1 | 1.93 | 2.23 |
| Dividends per Share |